跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 622 条关于
“elranatamab-bcmm”
全部
622
临床试验
347
药物
219
机构
1
资讯
55
9个月前
Elranatamab Plus Iberdomide Combination Achieves 95.5% Response Rate in Relapsed/Refractory Multiple Myeloma
2年前
Novel Targets and Strategic Sequencing: The Evolving Landscape of T-Cell Redirection Therapies in Multiple Myeloma
2年前
India's CDSCO Rejects Pfizer's Clinical Trial Waiver for Multiple Myeloma Drug Elranatamab
3年前
Elranatamab Achieves 61% Response Rate in Heavily Pretreated Multiple Myeloma Patients
去年
Elranatamab Consolidation Therapy Shows Promise in Deepening Response After CAR-T Treatment in Multiple Myeloma
2年前
NHS Scotland Approves Elranatamab and Teclistamab for Relapsed/Refractory Multiple Myeloma
3年前
Pfizer Launches Phase 3 Trial Testing Elranatamab Triple Combination for Newly Diagnosed Multiple Myeloma
12个月前
FAERS Analysis Reveals Lower Infection Risk with Ide-cel Compared to Other BCMA-Targeted Therapies in Multiple Myeloma
3年前
Novel BCMA-Targeted Therapies and Emerging Agents Transform Treatment Landscape for Relapsed/Refractory Multiple Myeloma
去年
Optimizing Treatment Strategies for Relapsed Multiple Myeloma: From CAR T-Cell Therapy to Novel Combinations
第 1 页,共 6 页
上一页
下一页